摘要
匹伐他汀(pitavastatin)是新一代人工合成的降血脂类药物。该药是新一代HMG-COA还原酶抑制剂,用于治疗原发型高脂血症和混合型血脂障碍,能够显著降低LDL、TC、TG、及升高HDL-C。药物动力学性质优良,具有肝细胞选择性,并且毒性低,安全性好,具有抗动脉粥样硬化、促进血管生成和抗炎作用。本文就匹伐他汀的临床研究进展进行综述。
Pitavastatin is the new generation of synthetic lipid-lowering drugs.The drug is a new generation of HMG-COA reductase inhibitor,for the treatment of the original hairstyle hyperlipidemia and mixed dyslipidemia,low-density lipoprote in cholesterol（LDL-C）,Total cholesterol（TC）,triglycerides（TG）,and also increase high-density lipoproteincho lesterol（HDL-C）.The drug iswell tolerated and safe.Itnotonly haspotent cholesterol-lowering effects,but also has anti-atherosclerotic,angioge-Nesis-promoting and anti-inflammatory effects by selectively acting on liverv cells.The advancement of pitavastatin in current clinic newest researches are reviewed in this article.
出处
《现代生物医学进展》
CAS
2014年第12期2383-2386,共4页
Progress in Modern Biomedicine
关键词
匹伐他汀
冠心病
降血脂
pitavastatin
Coronary heart disease
lipids-lowering
